Independent, principal-led AI architecture and unit-economics advisory for deal teams and operating partners. We eliminate hidden inference margin drag, harden non-human identities, and convert labor-heavy portfolio workflows into defensible, recurring software margins—without multi-year rip-and-replace CapEx.
Most portfolio companies treat generative AI as an experimental IT line item. Left unchecked, uncalibrated agents erode gross margins and introduce uninsurable tail risk.
When token and inference costs scale linearly with customer volume, software gross margins collapse toward services margins. We re-architect agentic pipelines to route, cache, and bound compute—preserving 75%+ gross margins at scale.
A 3-to-5-year hold period cannot absorb an 18-month core infrastructure rebuild. We deploy deterministic orchestration layers directly atop legacy ERPs and clinical/financial systems to automate high-cost human workflows inside two quarters.
Autonomous agents operating with over-privileged API keys represent an existential breach and compliance liability. We enforce zero-trust Non-Human Identity (NHI) and OpenTelemetry observability before a single workflow hits production.
Productized engagements aligned directly with investment lifecycle milestones.
Timeline: 10 to 15 Business Days
Target Buyer: Deal Teams & Investment Committees
Timeline: 6 to 8 Weeks
Target Buyer: Operating Partners & Portfolio CTOs
Timeline: Quarterly Advisory Retainer
Target Buyer: Operating Partners & Portfolio CEOs
Timeline: 3 to 4 Weeks (6–12 Mo Pre-Exit)
Target Buyer: Deal Teams & Sell-Side Advisors
| Mandate Type | Sector & Context | Intervention | Quantified Impact |
|---|---|---|---|
| Buy-Side Diligence | B2B Healthcare SaaS (Growth Buyout Target) | Audited target's "autonomous clinical coding" claims and modeled inference costs at projected 4x volume. | Uncovered $3.8M in unbudgeted annual LLM compute drag, enabling the deal team to re-trade valuation and ring-fence post-close remediation. |
| First 100 Days Hardening | Middle-Market FinTech (Post-Close Carve-Out) | Replaced shared static API credentials across 40+ automated reconciliation agents with scoped NHI and OpenTelemetry tracing. | Achieved zero-trust audit readiness in 6 weeks and reduced monthly inference spend by 42% via deterministic routing. |
| Margin Expansion | Life Sciences / Biopharma Services (Hold-Period Asset) | Layered deterministic agent orchestration over legacy LIMS and regulatory documentation workflows without core system replacement. | Cut manual review cycle times by 65%, shifting gross margins +900 bps over three quarters. |
Every engagement is led directly by former AWS automation leadership with $1.5B+ P&L accountability and 10 granted AI/ML patents—never handed off to junior analysts.
| Evaluation Criteria | Big 4 & Global SIs | Cloud Hyperscalers & AI Vendors | Agentic Path Group |
|---|---|---|---|
| Core Incentive | Maximize billable headcount & multi-year transformation fees | Maximize cloud compute & token consumption | Maximize portfolio EBITDA, gross margin & exit multiple |
| Staffing Model | Partner pitches; junior consultants execute | Solutions architects tied to product quotas | 100% Principal-led architectural & board execution |
| Diligence Speed | 4–6 weeks, heavy slide decks | Not built for M&A timelines | 10–15 business days, IC-ready red-flag memos |
| Vendor Neutrality | Often tied to alliance partnerships | Locked to proprietary stack | Strictly independent; zero vendor kickbacks |
We routinely execute under mutual NDA on compressed M&A timelines. Share your target window below for a direct, principal-to-principal scoping call within one business day.
Direct Scoping Contact: advisory@agenticpathgroup.com